Emmaus Life Sciences, Inc.
EMMA
$0.07
$0.019.23%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 218.77% | -48.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 218.77% | -48.55% | |||
| Cost of Revenue | 104.76% | -28.51% | |||
| Gross Profit | 229.33% | -49.85% | |||
| SG&A Expenses | -20.41% | -18.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.91% | -18.68% | |||
| Operating Income | 560.63% | -304.47% | |||
| Income Before Tax | 140.17% | -72.14% | |||
| Income Tax Expenses | -125.00% | -75.00% | |||
| Earnings from Continuing Operations | 140.15% | -70.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 140.15% | -70.94% | |||
| EBIT | 560.63% | -304.47% | |||
| EBITDA | 570.92% | -293.53% | |||
| EPS Basic | 140.21% | -57.28% | |||
| Normalized Basic EPS | 176.55% | -15.54% | |||
| EPS Diluted | 131.79% | -57.28% | |||
| Normalized Diluted EPS | 144.48% | -15.54% | |||
| Average Basic Shares Outstanding | 0.00% | 8.72% | |||
| Average Diluted Shares Outstanding | 71.73% | 8.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||